Associated Papers
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
41566785 (PubMed )
Supplement: mmc2.xlsx › Sheet1
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.
Chow RD et al.
Blood Advances, 2025
39938015 (PubMed )
Supplement: BLOODA_ADV-2024-015149-mmc2.xlsx › S2
Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemia.
Chow RD et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
39252918 (PubMed )
Supplement: media-1.xlsx › S1
Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis.
Uddin MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37732181 (PubMed )
Supplement: media-2.xlsx › Table_S3
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms.
Chovanec J et al.
Blood Advances, 2023
36170795 (PubMed )
Supplement: BLOODA_ADV-2022-007936-mmc1.pdf
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
35650444 (PubMed )
Supplement: 41586_2022_4785_MOESM11_ESM.xlsx › historical_growth
Driving mosaicism: somatic variants in reference population databases and effect on variant interpretation in rare genetic disease.
Avramović V et al.
Human Genomics, 2021
34906245 (PubMed )
Supplement: 40246_2021_371_MOESM1_ESM.xlsx › S5
Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
Nagata Y et al.
Blood, 2016
Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
Saint-Martin C et al.
Blood, 2009
Select a paper to view details